Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients

Inclusion Criteria:

1. Age 18-75 years; ECOG score 0-1.
2. Histologically or cytologically confirmed small cell lung cancer.
3. Limited stage, defined as the tumor confined to one side of the thoracic cavityincluding ipsilateral hilar, bilateral mediastinal, and bilateral supraclavicularlymph nodes, (metastatic lymph nodes are defined as short diameter ≥ 1 cm or increasedmetabolism on PET-CT considering metastatic lymph nodes); unless cytologicallyconfirmed malignant pleural effusion, the thickness of pleural effusion on chest CT isless than 1 cm; (stage I-IIIB without intrapulmonary metastasis in the 7th edition ofAJCC staging in 2009) .
4. No other previous anti-tumor history, at least 3 months of expected survival.
5. No serious medical diseases and dysfunction of major organs, such as blood routine,liver, kidney, heart and lung function.

Exclusion Criteria:

1. Histologically or cytologically confirmed mixed SCLC.
2. Subjects suitable for surgery. Subjects who are suitable for surgery but refusesurgical treatment can be included.
3. Patients who have previously received systematic anti-tumor treatments for small celllung cancer, including but not limited to radiotherapy, chemotherapy, andimmunotherapy.
4. Patients with other active malignancies within 5 years or at the same time.
5. Subjects with known history of severe allergy to any monoclonal antibody.
6. Subjects with known anaphylaxis to carboplatin/cisplatin or etoposide.
7. In the judgment of the investigator, subjects who have any other factors that may leadto a premature discontinuation.